A previous study using in vitro HER2-positive breast cancer cell lines, which expressed wild-type oestrogen receptor, such as SKBR3, showed that neratinib treatment repressed the activity of nuclear factor-erythroid factor 2-related factor 2 (NRF2), a master regulator of antioxidant defence, to then promote oxidative-stress-dependent cell death [12]. Here, ERBB2 is linked to breast carcinoma.